CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER: 19-430/S054

Trade Name: EpiPen®

Generic Name: epinephrine

Sponsor: Mylan Specialty L.P.

Approval Date: 7/23/2013
## Contents

Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Review Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>✓</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td></td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td>✓</td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td>✓</td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Other Reviews</td>
<td></td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>✓</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
19-430/s054

APPROVAL LETTER
NDA 19430/S-054

Meridian Medical Technologies, Inc.
Attention: Ellen Kay Loscuito
Manager, Regulatory Affairs
1945 Craig Road
St. Louis, MO 63146

Dear Ms. Loscuito:

Please refer to your Supplemental New Drug Application (sNDA) submitted February 6, 2013 and received February 7, 2013, under section 505(b) of the Federal Food, Drug, and Cosmetic Act for EpiPen® and EpiPen® Jr (Epinephrine) Auto-Injector.

This “Changes Being Effect in 30 days” supplemental application proposes [REDACTED] with a [REDACTED] in the [REDACTED] area.

We have completed our review of this supplemental new drug application. This supplement is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Youbang Liu, Regulatory Project Manager, at (301) 796-1926.

Sincerely,

See appended electronic signature page

Ramesh Raghavachari, Ph.D.
Acting Branch Chief, Branch IX
Division of New Drug Quality Assessment III
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAMESH RAGHAVACHARI
07/23/2013
APPLICATION NUMBER:
19-430/s054

CHEMISTRY REVIEW(S)
## Chemistry Review #1

<table>
<thead>
<tr>
<th>1. ONDQA (HFD-510)</th>
<th>2. NDA/Suppl. Number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>19-430/S-054</td>
</tr>
</tbody>
</table>

### 3. Name and Address of Applicant
Meridian Medical Technologies – a Pfizer Co.
Attention: Ellen Kay Losciuto, CQA, RAC
1945 Craig road, St. Louis, MO 63146

### 4. Date of:
Submission: 2/6/13
User Fee: 8/7/13

### 5. Name of Drug: Epipen Auto-injector
### 6. Nonproprietary Name: Epinephrine injection

### 7. Supplement, CBE-30, Provides for:

### 8. Amendment(s):

### 9. Pharmacological Category

### 10. How Dispensed: Rx

### 12. Dosage Form: Injection
### 13. Potency(ies):

### 15. Drug Name: Epinephrine, R-(-)-Epinephrine or R-(-)-L-adrenaline

### Structure:

![Epinephrine Structure](image)

### 16. Comments:
1. Division of Microbiology has reviewed the submission and recommended approval of the supplemental application. Review is available in DARRTS.
2. No other CMC changes are associated to this supplemental application.

### 17. Conclusions and Recommendations: Recommend approval.

### 18. Name:
Review Chemist: Bart Ho, Chemist
Acting Branch Chief
Ramesh Raghavacheri Ph.D.

19430S054 Micro Meridian

---

1 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BARTHOLOME C HO
07/22/2013

RAMESH RAGHAVACHARI
07/22/2013
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
19-430/s054

MICROBIOLOGY REVIEW(S)
Product Quality Microbiology Review

14 June 2013

NDA: 19-430/S-054

Drug Product Name

Proprietary: EpiPen® and EpiPen® Jr Auto Injectors
Non-proprietary: Epinephrine Injection

Review Number: 1

Dates of Submission(s) Covered by this Review

<table>
<thead>
<tr>
<th>Submit</th>
<th>Received</th>
<th>Review Request</th>
<th>Assigned to Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/06/2013</td>
<td>02/07/2013</td>
<td>04/26/13</td>
<td>05/02/13</td>
</tr>
</tbody>
</table>

Submission History (for 2nd Reviews or higher) – N/A

Applicant/Sponsor

Name: Meridian Medical Technologies, Inc.
Address: 1945 Craig Road, St. Louis, MO 63146
Representative: Ellen Kay Losciuto
Telephone: 314-682-3088

Name of Reviewer: Neal J. Sweeney, Ph.D.

Conclusion: Recommended for Approval
Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: CBE-30 Supplement

2. SUBMISSION PROVIDES FOR: 

3. MANUFACTURING SITE: Meridian Medical Technologies, Inc.

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY: sterile injectable solution (0.3 mg/0.3 mL, 0.15 mg/0.3 mL) in EpiPen® and EpiPen® Jr. Auto Injectors, for IM injection

5. METHOD(S) OF STERILIZATION: 


B. SUPPORTING/RELATED DOCUMENTS: was approved under NDA 19-430/S-032 on August 16, 2006.

C. REMARKS: 

filename: N19430S054R1.doc
Executive Summary

I. Recommendations

A. Recommendation on Approvability - Recommended for Approval.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable – Not applicable

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – The drug product is [Redacted]. The applicant proposes to [Redacted].

B. Brief Description of Microbiology Deficiencies – No microbiology deficiencies were identified based upon the information provided.

C. Assessment of Risk Due to Microbiology Deficiencies – Not applicable

D. Contains Potential Precedent Decision(s) - [ ] Yes [X] No
   (If yes, provide a brief description and a reference to the page where the precedent is discussed in depth)

III. Administrative

A. Reviewer’s Signature __________________________
   Neal J. Sweeney, PhD

B. Endorsement Block
   Bryan S. Riley, PhD  Acting Microbiology Team Leader

C. CC Block
   N/A

4 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------------------------------
NEAL J SWEENY
06/17/2013

BRYAN S RILEY
06/17/2013
I concur.
**DEPARTMENT OF HEALTH AND HUMAN SERVICES**
**PUBLIC HEALTH SERVICE**
**FOOD AND DRUG ADMINISTRATION**

**CMC MICRO & STERILITY ASSURANCE**
**REVIEW REQUEST**

**TO (Division/Office):** New Drug Microbiology Staff  
**E-mail to:** CDER OPS IO MICRO  
**Paper mail to:** WO Bldg 51, Room 4193

**FROM:** Youbang Liu, ONDQA (301-796-1926)  
**PROJECT MANAGER (if other than sender):**

<table>
<thead>
<tr>
<th>REQUEST DATE</th>
<th>IND NO.</th>
<th>NDA NO.</th>
<th>TYPE OF DOCUMENT</th>
<th>DATE OF DOCUMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/26/2013</td>
<td></td>
<td>19430/S-054</td>
<td>CBE-30 Supplement</td>
<td>2/7/13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NAMES OF DRUG</th>
<th>PRIORITY CONSIDERATION</th>
<th>PDUFA DATE</th>
<th>DESIRED COMPLETION DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPIPEN JR</td>
<td></td>
<td>8/8/13</td>
<td>6/25/13</td>
</tr>
</tbody>
</table>

| NAME OF APPLICANT OR SPONSOR: | MERIDIAN MEDICAL TECHNOLOGIES INC. |

**REQUEST DATE:** 4/26/2013  
**IND NO.:** 19430/S-054  
**NDA NO.:** 19430/S-054  
**TYPE OF DOCUMENT:** CBE-30 Supplement  
**DATE OF DOCUMENT:** 2/7/13  

**NAMES OF DRUG:** EPIPEN JR  
**PRIORITY CONSIDERATION:**  
**PDUFA DATE:** 8/8/13  
**DESIRED COMPLETION DATE:** 6/25/13  

**NAME OF APPLICANT OR SPONSOR:** MERIDIAN MEDICAL TECHNOLOGIES INC.  

**GENERAL PROVISIONS IN APPLICATION**

- [ ] 30-DAY SAFETY REVIEW NEEDED  
- [ ] NDA FILING REVIEW NEEDED BY:  
- [ ] BUNDLED  
- [ ] DOCUMENT IN EDR  
- [ ] CBE-0 SUPPLEMENT  
- [ ] CBE-30 SUPPLEMENT  
- [ ] CHANGE IN DOSAGE, STRENGTH / POTENCY

**COMMENTS / SPECIAL INSTRUCTIONS:**

The micro information needs to be reviewed.

Paper submission, a jacket will be delivered to Micro Staff.

**SIGNATURE OF REQUESTER:** Youbang Liu

**REVIEW REQUEST DELIVERED BY (Check one):**

- [ ] DARRTS  
- [ ] EDR  
- [ ] E-MAIL  
- [ ] MAIL  
- [ ] HAND

**DOCUMENTS FOR REVIEW DELIVERED BY (Check one):**

- [ ] EDR  
- [ ] E-MAIL  
- [ ] MAIL  
- [ ] HAND

Reference ID: 3300000
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

YOUBANG LIU
04/26/2013
Dear Ms. Losciuto:

We have received your Supplemental New Drug Application (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) for the following:

**NDA NUMBER:** 19430

**SUPPLEMENT NUMBER:** S-054

**PRODUCT NAME:** EpiPen® and EpiPen® Jr (Epinephrine) Auto-Injector

**DATE OF SUBMISSION:** February 6, 2013

**DATE OF RECEIPT:** February 7, 2013

This supplemental application, submitted as a “Changes Being Effected in 30 days” supplement, proposes to ___(0)(e)___ with a ___(0)(e)___ in the ___(0)(e)___ area.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on April 8, 2013, in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be August 7, 2013.

Cite the application number listed above at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

Reference ID: 3270100
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Pulmonary, Allergy and Rheumatology Products
5901-B Ammendale Road
Beltsville, MD 20705-1266

All regulatory documents submitted in paper should be three-hole punched on the left side of the page and bound. The left margin should be at least three-fourths of an inch to assure text is not obscured in the fastened area. Standard paper size (8-1/2 by 11 inches) should be used; however, it may occasionally be necessary to use individual pages larger than standard paper size. Non-standard, large pages should be folded and mounted to allow the page to be opened for review without disassembling the jacket and refolded without damage when the volume is shelved. Shipping unbound documents may result in the loss of portions of the submission or an unnecessary delay in processing which could have an adverse impact on the review of the submission. For additional information, see http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/ucm073080.htm.

If you have questions, call me, at (301) 796-1926.

Sincerely,

{See appended electronic signature page}

Youbang Liu
Regulatory Project Manager
Division III of New Drug Quality Assessment
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

YOUBANG LIU
03/01/2013